Condition: Transthyretin-type Cardiac Amyloidosis · Sponsor: Alexion Pharmaceuticals, Inc.
The purpose of this study is to confirm that the treatment with acoramidis prevents the deterioration of the ATTR-CM disease progression index and that these indexes are surrogate markers of disease progression.
This description comes directly from the study's public registry record.
Alexion Pharmaceuticals, Inc. (Sponsor) · 1-855-752-2356 · clinicaltrials@alexion.com
Always discuss trial participation with your own doctor first.
| Research Site | Bunkyō City, Japan | Not Yet Recruiting |
| Research Site | Bunkyō City, Japan | Not Yet Recruiting |
| Research Site | Kumamoto, Japan | Not Yet Recruiting |
| Research Site | Kurume-shi, Japan | Recruiting |
| Research Site | Kyoto, Japan | Not Yet Recruiting |
| Research Site | Mitaka-shi, Japan | Not Yet Recruiting |
| Research Site | Nagoya, Japan | Not Yet Recruiting |
| Research Site | Nankoku-shi, Japan | Not Yet Recruiting |
| Research Site | Okayama, Japan | Not Yet Recruiting |
| Research Site | Ōtsu, Japan | Not Yet Recruiting |
| Research Site | Sagamihara-shi, Japan | Not Yet Recruiting |
| Research Site | Sapporo, Japan | Not Yet Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07306949